Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vivus: into single digits -- Ignore unavailable to you. Want to Upgrade?

To: Bradpalm1 who wrote (923)	8/28/1998 11:45:00 PM
From: AlienTech	Read Replies (1) \| Respond to of 1016

Well I have seen some real hype jobs both long and short. But untill you have real data, you have nothing but speculation. VVUS is not the only stock to crash and burn, Most small caps are burning. So are they all hyped long jobs? I doubt it, I think its just fear and people sell for what ever they can get. After all if people never bought in such companies how are the shorts going to make their killing? In the market you win some and you loose some. The ones who win in the long term are the ones who learn.

To: Bradpalm1 who wrote (923)	8/29/1998 11:31:00 AM
From: BigKNY3	Read Replies (3) \| Respond to of 1016

Brad and Mike: Since the VVUS Board is unfortunatley becoming Yahooed, I have returned to the Single Digits Board for a discussion of issues and honest opinions concerning VVUS and the ED market. Brad: The San Francisco Chronicle article does bring out the truth about Wole Fayemi....probably the worst Pharma analyst that you could ever hope to find. Wole's reports have been touting VVUS since his days as the VVUS analyst for Genesis ...which just happened to do investment banking for VVUS. In October, 1997, he moved to Cruttenden and Roth. Let's take a look at Wole Fayemi's unique insight into VVUS: March 3, 1997 (VVUS @ 27 5/8): Reiterated Strong Buy raising VVUS price target to $75 from $42 1/2. Forecasts MUSE sales at $140M (1997), $300M (1998) and $700M (1999). October 10, 1997 (VVUS @ 36 1/6): Despite the submission of Viagra NDA to the FDA in September, initiated coverage as new CR analyst on VVUS with a Buy and as price target of $75. April 23, 1998 (VVUS @ 8): Raised VVUS' Neutral rating to Strong Buy and set a 1998 price target of $23. Believes Viagra may be effective in only 50% of erectile dysfunction patients and that many patients "may turn to MUSE treatment for impotence"...VVUS "will reap rewards from PFE's marketing campaign which will likely increase the number of men seeking drugs for erectile dysfunction." May 1998: Wole Fayemi reportedly attempts to support his reports by calling "journalists with documented disclosures about deaths associated with Viagra's clinical trials." August 28, 1998 (VVUS @ 3 7/8): Maintains Strong Buy on VVUS BigKNY3

To: Bradpalm1 who wrote (923)	8/31/1998 7:39:00 PM
From: BDR	Read Replies (3) \| Respond to of 1016

A pertinent quote from the SF Chronicle article you cited a few days ago: ''A lot of people listen to the Wall Street hype. But with medical device stocks, the truth lies with the opinions of the clinicians,'' a buy-side analyst says. I would agree. In my opinion the main reason VVUS is trading near $3 is not the management, not the blatant hype from mercenary analysts (though hype and poor management are a setup for disappointment), and it is definitely not the shorts. The main reason is the product. If you can't get an erection pay $23 and poke a stick in it. If that doesn't work, cinch it up with a rubber band and poke a stick in it and it will work less than 50% of the time. In the absence of other less costly, less invasive, less effective choices, there will be a market for this stuff. In the presence of less costly, less invasive and more effective choices (Viagra now, more to come) the market will consist of the small number of really motivated people who have failed the preferred choices. That is a small number, ergo a small price for this stock.